Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Worldwide Offices
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Empowering Arthritis Disease Players with Disease Insights, Epidemiology Study, Unmet Needs Analysis, KOL Perspectives Drug Development Plans, and Regulatory Consulting Services| Disease Landscape Insights

      This image opens in the lightbox

      News provided by

      Disease Landscape Insights

      09 Oct, 2023, 14:15 GMT

      Share this article

      Share this article


      LONDON, Oct. 9, 2023 /PRNewswire/ -- Arthritis Disease is a joint-related ailment affecting numerous individuals across the globe. According to a data by the World Health Organization, more than 18 million people are living with rheumatoid arthritis.  Continuous arthritis research activities are going on with the sole aim to reduce the disease burden by developing effective diagnostic, management, treatment, and preventive solutions.

      Arthritis is a disease characterized by the inflammation of body joints. It leads to excessive pain, swelling, joint stiffness postural deformity, and other additional symptoms. The two primary sub types of this ailment are osteoarthritis which is often associated with aging and rheumatoid arthritis with is an immune disease and can occur at any age.

      Disease Landscape Insights healthcare consulting services are being procured by the industry players at a large scale. DLI plays a vital role in the management of arthritis by offering a comprehensive range of services and expertise. Its services encompasses clinical trial assessment, epidemiology study, and disease burden analysis, which provide valuable insights into the nature and impact of arthritis. Furthermore, it assists in drug development and drug launch strategies, ensuring that innovative treatments reach patients effectively. Pricing and reimbursement strategies, along with market access expertise, help bridge treatment gaps and ensure accessibility for patients. With regulatory consulting and clinical trial management, it facilitates the development and approval of new arthritis therapies. DLI contributes significantly to arthritis management by conducting product portfolio analysis and product pipeline assessments, identifying opportunities for product portfolio extension, and formulating commercial strategies to optimize patient care and outcomes.

      Price and Market Access

      Characteristics, Causes, and Symptoms:

      This disease is caused by the combination of different factors, primarily natural aging process, genetic factors, infections, and metabolic disorders. Sometimes, it is also triggered with the immune system mistakenly attacks the joint lining. Many people witness arthritis in fingers and arthritis in knees with their symptoms encompassing pain, swelling, and stiffness in the finger joints and difficulty in bending or straightening the knee respectively.  When any such symptom appears, it is crucial for people to seek advice from an arthritis specialist or join arthritis support groups before it gets too late and the risk of complication increases.

      Diagnosis and Treatment:

      In order to accurately detect this ailment, a thorough physical examination, medical history tests, imaging tests like MRI, CT scans, and X-rays, joint fluid analysis tests, and certain blood tests are recommended by physicians.

      Learn More About the FDA NDA & BLA Approval (NME) Drugs for Arthritis Disease @

      https://www.diseaselandscape.com/requestsample/postid/51 

      Post diagnosis, arthritis medications including pain relievers, DMARDs, biologics, and corticosteroids are administered.  In severe cases, arthritis surgery options like joint replacement are recommended. Apart from that there are other arthritis relief products and therapies that can transform the lives of the patients.

      People also opt for natural arthritis remedies to aid arthritis prevention and treatment. Arthritis management is often personalized to the patient's needs and may involve a combination of these treatment options. Regular monitoring and follow-up with a healthcare provider are essential to adjust treatment as needed and ensure the best possible outcome.

      Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

      https://www.diseaselandscape.com/checkout?report_id=51 

      Final Words:

      Arthritis in a joint disorder that may last a lifetime if not treated early. It leads to excessive pain, swelling, inflammation, and postural deformity. Age, genetics, infection, and metabolic factors may result in the onset of this ailment. A wide range of treatment options in the form of drugs, therapies, and surgeries have been developed so far. DLI has been helping players in their aim to develop more effective and advanced treatment solutions by aiding treatment gaps identification, clinical trial feasibility analysis, commercial strategy analysis, while equipping them with complete disease overview and existing drug insights.

      Browse Through More Chronic Diseases Research Reports.

      Related Reports:

      Advancing research into Parkinson's Disease Global Perspectives and Innovations in Care

      Unlocking the Most Recent Advances in Alzheimer's Disease research: a glimmer of hope

      Global Insights on Multiple System Atrophy (MSA) Disease: Rising Against the Odds

      Understanding Crohn's Disease: Its Causes, Signs, and Treatment

      Effective Psoriasis Disease Management Techniques: Unlocking Relief

      Managing the Alzheimer's Landscape: How We Direct Market Participants to Unique Solutions

      Healthcare is being revolutionized by AI-driven Personalized Medicine.

      New Topical Drug Delivery Therapies Unlock the Future of Skin-Credible Care, Causing a Psoriasis Care Crisis!

      By Lexicon Pharmaceuticals, whose , Inpefa endorsed by the FDA

      The drug Xacduro from Innoviva Specialty Therapeutics will aid in the Treatment of Bacterial Pneumonia

      Phase III Trials Show Effective Performance of Levodopa/Carbidopa's New Formulation ND0612: A Struggle Against Parkinson's Disease

      Lotilaner as a Revolutionary Demodex Blepharitis Treatment

      Elfabrio's Active Ingredient, Pegunigalsidase Alfa-IWXJ, May Aid in the Treatment of Fabry Disease

      The Roadmap for a Successful Drug Launch's

      Enabling Investor Excellence: Your Partner in Closing Gaps, Increasing Competitiveness, and Making a Global Impact

      Managing the Immunotherapy World's Challenges

      A case study involving the cooperation of a pharmaceutical business with CDMOs and SMOs

      Case Study: Expansion of the Australian Product Portfolio

      AI application in a healthcare organization: a case study

      Case Study: Landscape Analysis of Ovarian Cancer Treatment

      About Disease Landscape:  

      Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

      Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

      Contact Us: 
      Disease Landscape Insights LLP 
      6th Floor, Sr No.207, Office A H 6070 Phase 1 
      Solitaire Business Hub, Viman Nagar 
      Pune, Maharashtra, 411014 
      Email: ajay@diseaselandscape.com    
      Email: vishal@diseaselandscape.com
      Sales: +44-2038074155 
      Asia Office: +917447409162
      Blog: https://www.diseaselandscape.com/blogs
      Case Study: https://www.diseaselandscape.com/casestudies    
      Pharma consulting Services 
      Follow Us: LinkedIn | Twitter | Facebook

      Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.